PATIENCE, page-34

@sarge17

Thanks for asking, but I do sleep very well at present. I hope you are too - but do you ever get that FOMO feeling ...

@col69

I take a contrarian position to views that the Internal DEP is a big flop and on where the SP will go from here. There really is no hard evidence to date (other than things are progressing well) so I think there is a bit of straw clutching going on.

Timeframes have gone beyond our expectations - does that necessarily mean failure? No.

Most of us have been following SPL for years, and one must be prepared to play the long game when in biotech - that's why the rewards can be worth it. I'm definitely with everyone though, that us LT holders want some reward now

Major contributing reason as to why our SP is floundering at present -

Article: Biotech correction (dated 13 July 2022)

Correction biotech had to have
The listed biotech sector has been sold off hard over the past year. The S&P Biotechnology Select Industry Index fell 15.8% in 2021 and ~38% so far this year. While there’s not an equivalent index in Australia, the S&P/ASX 300 Healthcare Index is down ~8% and doesn’t include the small clinical stage biotechs which have been hit hard.

Also, ask yourself why someone of Dr Jeff Davies' calibre and experience/skills joined SPLs Board of Directors this year? Free ride, or strategically brought in now to provide guidance on any potential licencing deals...

Announcements are coming, we just don't know when, although our Annual Report is coming later this month - maybe we'll get more answers rather than questions by then...

GLTAH